Showing 1 - 5 results of 5 for search 'Jason John Luke', query time: 0.02s Refine Results
  1. 1
    ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

    ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19 by Lei Huang, Riyue Bao, Kyle Hernandez, Jason John Luke

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

    Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer by Thomas Marron, Brett G M Hughes, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, Richard A Miller, William B Jones, Jaime R Merchan, Stephen B Willingham

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

    Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716... by Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

    Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy by Dirk Schadendorf, Celeste Lebbe, Teresa Amaral, Benjamin Weide, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Reinhard Dummer, Domenico Mallardo, Paolo A Ascierto, Piotr Rutkowski, Jason John Luke, Kilian Wistuba-Hamprecht, Mitchell P Levesque, Roberta Turiello, Elva Morretta, Maria Chiara Monti, Rosa Azzaro, Laurence Imhof, Marc Chevrier, Antje Sucker, Aldo Pinto, Silvana Morello

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

    First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

    Published 2024-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: